Text Size

Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients (MUNIN)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00494780
First received: June 29, 2007
Last updated: February 2, 2012
Last verified: January 2012
History of Changes
Results First Received: July 28, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Lymphoma, Follicular
Interventions: Drug: Ofatumumab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisolone, Prednisone or equivalent

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
500 mg Ofatumumab + CHOP Ofatumumab was given on Day 1 and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) on Day 3 of each 21-day cycle, with 300 milligrams (mg) in Cycle 1 and 500 mg in Cycles 2 to 6.
1000 mg Ofatumumab + CHOP Ofatumumab was given on Day 1 and CHOP on Day 3 of each 21-day cycle, with 300 mg in Cycle 1 and 1000 mg in Cycles 2 to 6.

Participant Flow:   Overall Study
    500 mg Ofatumumab + CHOP     1000 mg Ofatumumab + CHOP  
STARTED     29     30  
COMPLETED     18     17  
NOT COMPLETED     11     13  
Adverse Event                 3                 4  
Entered Follow-up Study                 1                 0  
Withdrew Before Dosed; Entered Follow-up                 0                 1  
Progression of Study Disease                 7                 8  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
500 mg Ofatumumab + CHOP Ofatumumab was given on Day 1 and CHOP on Day 3 of each 21-day cycle, with 300 mg in Cycle 1 and 500 mg in Cycles 2 to 6
1000 mg Ofatumumab + CHOP Ofatumumab was given on Day 1 and CHOP on Day 3 of each 21-day cycle, with 300 mg in Cycle 1 and 1000 mg in Cycles 2 to 6
Total Total of all reporting groups

Baseline Measures
    500 mg Ofatumumab + CHOP     1000 mg Ofatumumab + CHOP     Total  
Number of Participants  
[units: participants]
 		  29     29     58  
Age [1]
[units: Years]
Mean ± Standard Deviation 		  54.1  ± 11.4     53.7  ± 9.14     53.9  ± 10.2  
Gender [1]
[units: Participants]
 		     
Female     14     21     35  
Male     15     8     23  
Race/Ethnicity, Customized [1]
[units: participants]
 		     
White     29     27     56  
Hispanic or Latino     0     2     2  
[1]

Baseline characteristics were collected in the Full Analysis Set (FAS), comprised of all participants who were exposed to trial drug irrespective of their compliance to the planned course of treatment.

One participant was enrolled and randomized to receive 1000 mg Ofatumumab + CHOP, but withdrew prior to initiation of therapy.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants Classified as Responders at Visit 26 (3 Months After Last Infusion of Ofatumumab)   [ Time Frame: Maximum of 23 months after the start of treatment ]
  Show Outcome Measure 1

2.  Primary:   Number of Participants With the Indicated Overall Best Response (OBR) at Visit 26 (3 Months After the Last Infusion of Ofatumumab)   [ Time Frame: Maximum of 23 months after the start of treatment ]
  Show Outcome Measure 2

3.  Secondary:   Number of Participants With Complete Remission (CR) at Visit 26   [ Time Frame: Maximum of 23 months after the start of treatment ]
  Show Outcome Measure 3

4.  Secondary:   Median Percent Change From Visit 1 (Screening, Week -2) in Tumor Size at Visit 33 (24 Months After the Last Infusion of Ofatumumab)   [ Time Frame: Maximum of 24 months after the last infusion of Ofatumumab (Visit 33; median of 33.8 months) ]
  Show Outcome Measure 4

5.  Secondary:   Percent Change From Visit 1 (Screening) in Peripheral CD19+ and CD20+ Cell Counts at Visit 33 (24 Months After the Last Infusion of Ofatumuab)   [ Time Frame: Maximum of 24 months after the last infusion of Ofatumuab (Visit 33; median of 33.8 months) ]
  Show Outcome Measure 5

6.  Secondary:   Number of Participants Who Experienced Any Adverse Event (AEs) From First Treatment to Visit 33 (24 Months After Last Infusion)   [ Time Frame: Up to 22 months after study start ]
  Show Outcome Measure 6

7.  Secondary:   Median Percent Change From Visit 1 (Screening) in Serum Complement (CH50) Levels at Visit 22   [ Time Frame: Visit 1 (Screening, Week -2) and Visit 22 (Week 15) ]
  Show Outcome Measure 7

8.  Secondary:   Cmax and Ctrough at the Sixth Infusion (Week 15, Visit 22)   [ Time Frame: Week 15 (Visit 22) ]
  Show Outcome Measure 8

9.  Secondary:   AUC(0-inf) and AUC(0-504) After the Sixth Infusion (Week 15, Visit 22)   [ Time Frame: Week 15 (Visit 22) ]
  Show Outcome Measure 9

10.  Secondary:   Half Life (t1/2) of Ofatumumab at the Sixth Infusion (Week 15, Visit 22)   [ Time Frame: Week 15 (Visit 22) ]
  Show Outcome Measure 10

11.  Secondary:   CL After the Sixth Infusion (Week 15, Visit 22)   [ Time Frame: Week 15 (Visit 22) ]
  Show Outcome Measure 11

12.  Secondary:   Vss at the Sixth Infusion (Week 15, Visit 22)   [ Time Frame: Week 15 (Visit 22) ]
  Show Outcome Measure 12

13.  Secondary:   Progression-Free Survival (PFS)   [ Time Frame: Followed up for up to 6 years ]
Results not yet posted.   Anticipated Posting Date:   06/2014   Safety Issue:   No

14.  Secondary:   Time to Next Anti-follicular Lymphoma (FL) Therapy   [ Time Frame: Followed up for up to 6 years ]
Results not yet posted.   Anticipated Posting Date:   06/2014   Safety Issue:   No

15.  Secondary:   Duration of Response   [ Time Frame: Followed up for up to 6 years ]
Results not yet posted.   Anticipated Posting Date:   06/2014   Safety Issue:   No

16.  Secondary:   Number of Participants With Positive Human Anti-human Antibodies (HAHA) at Visits 1, 28, and 33   [ Time Frame: Visits 1 (Screening), 28 (9 months after last dose), and 33 (24 months after last dose) ]
Results not yet posted.   Anticipated Posting Date:   06/2014   Safety Issue:   No

17.  Secondary:   Conversion of BCL-2 t(14;18)-Positivity by Polymerase Chain Reaction (PCR) in Peripheral Blood and Bone Marrow Aspirate and Its Durability Post-therapy   [ Time Frame: Maximum of 6 years follow-up ]
Results not yet posted.   Anticipated Posting Date:   06/2014   Safety Issue:   No


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343


No publications provided by GlaxoSmithKline

Publications automatically indexed to this study:


Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier: NCT00494780     History of Changes
Other Study ID Numbers: 111775, Hx-CD20-409, The MUNIN trial
Study First Received: June 29, 2007
Results First Received: July 28, 2011
Last Updated: February 2, 2012
Health Authority: United States: Food and Drug Administration